EPH3 Effectiveness of Additional Risk Minimization Measures When Using Baricitinib (RISK-BARI): Preliminary Analysis
Year: 2024
Type: article
Abstract: Baricitinib, a JAK1 and JAK2 inhibitor, treats moderate to severe rheumatoid arthritis, atopic dermatitis, and severe alopecia areata in adults. Additional risk minimization measures (aRMMs) include educational materials to mitigate the risks of malignancies, major adverse cardiovascular events, serious infections, venous thromboembolism, and mortality. These materials include a Healthcare Professionals (HCP) Guide, a Patient Alert Card (PAC), and Direct Healthcare Professional Communications (DHPC).
Source: Value in Health
Authors: A.M. Silva, A Moreira, L Jacinto, A Gamboa, JP Fernandes, M Silva, M Melo
Language: English
Subfield: Toxicology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $3,200
OpenAlex ID: W4405747966